



DIVIDEND PAYERS



GO TO
PORTLAND GLOBAL
BALANCED FUND¹

AT&T - Nokia announced it has signed a multi-year agreement with AT&T to deploy next-generation fiber access technology. Under this agreement, Nokia will provide its Lightspan MF and Altiplano Access Controller platforms to support one of the largest fiber networks in the world. The five-year deal will include fiber network upgrades to AT&T's current footprint and next-generation fiber technologies for future network expansions and is Build America, Buy America-compliant. This strategic collaboration represents a significant milestone, establishing the network foundation essential for the next generation of broadband services. With Nokia's fiber solutions, AT&T can quickly establish a future-ready network capable of addressing the growing demand for more capacity and enhanced broadband services. Designed to support a range of next-generation Passive Optical Network (PON) technologies, from 10/25/50/100G (Gigabit Ethernet), Nokia's Lightspan platform gives AT&T the choice and flexibility to optimize its network to its specific business case and needs. Nokia's Altiplano Access Controller will also help drive higher levels of automation in AT&T's network and service operations.

ATCO - ATCO Structures & Logistics Ltd. (ATCO Structures) has successfully closed the previously announced acquisition of NRB Limited (NRB), a leading Canadian manufacturer of modular industrial, educational and residential buildings, from Dexterra Group Inc. The purchase, completed for US\$40 million in cash, was subject to normal closing adjustments and conditions, including final authorization of the Canadian Competition Bureau. ATCO Structures continues to expand its global presence by introducing new forms of modular construction and expanding our offering of modular products, with significant recent expansion in residential product lines. "The NRB acquisition, along with our recent purchase of Triple M Housing, the Canadian leader in single family modular housing, has led to the dramatic growth and diversification of ATCO Structures and now positions our future operations to provide a full suite of commercial, industrial, education and all forms of residential modular products across Canada and competitively into the United States," said Adam Beattie, President, ATCO Structures.



LIFE SCIENCES



GO TO
PORTLAND LIFE
SCIENCES
ALTERNATIVE FUND¹

Beigene, Ltd. (Beigene) – The US Food and Drug Administration (FDA) has granted fast-track designation for BeiGene's BGB-16673 to treat adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). BGB-16673 is designed for patients who have undergone a minimum of two prior lines of therapy, including a BTK inhibitor (BTKi) and a B-cell lymphoma 2 (BCL2) inhibitor. Data from the ongoing first-in-human Phase I/II trial have shown that BGB-16673 has a tolerable safety profile and promising efficacy in

heavily pretreated relapsed or refractory (R/R) CLL/SLL patients. More than 300 subjects have been treated so far across 15 countries as part of the global clinical development programme for BGB-16673. The therapy is designed to induce degradation of both wildtype and multiple mutant forms of BTK, including those mutations that commonly confer resistance to BTK inhibitors in patients with progressive disease. BeiGene haematology chief medical officer Mehrdad Mobasher stated: "The FDA's fast track designation supports our goal of efficiently developing BGB-16673 for these patients, the first investigational drug from our Covalent Drug-Active Compound (CDAC) platform.

BridgeBio Pharma, Inc. (BridgeBio) – shared new data from the company's Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM) study, showing that participants who switched from placebo or tafamidis to acoramidis experienced significant increases in serum transthyretin (TTR) levels. Acoramidis, a TTR stabilizer for the treatment of a specific type of cardiovascular disease, showed substantial benefits in reducing mortality, hospitalizations, and improving quality of life, with a 42% reduction in composite cardiovascular events and a 50% reduction in cardiovascular-related hospitalizations by Month 30 compared to placebo.

Telix Pharmaceuticals Limited (Telix) – has submitted a New Drug Application (NDA) to the U.S. FDA for TLX101-CDx (Pixclara®), an investigational Positron Emission Tomography (PET) imaging agent for detecting progressive or recurrent glioma in both adults and children. Pixclara® has been granted Orphan Drug and Fast Track designations due to its potential to address a significant unmet medical need. While FET (Fluoroethyl-L-tyrosine) PET, the basis for Pixclara®, is already used internationally for glioma imaging, there is currently no FDA-approved targeted amino acid PET agent in the U.S. for brain cancer. Upon approval, Pixclara® could improve diagnosis and management of glioma, especially in post-treatment settings, and it also serves as a companion imaging agent for Telix's investigational therapeutic, TLX101.

Telix announced a reorganization to better align with its strategic priorities as a therapeutics-led radiopharmaceutical company focused on precision oncology. The company has restructured into four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Key leadership changes include Richard Valeix as CEO of Telix Therapeutics, Kevin Richardson as CEO of Telix Precision Medicine, and Raphael Ortiz as CEO of Telix International. Darren Patti remains as Group Chief Operating Officer (COO), overseeing manufacturing operations. Dr Christian Behrenbruch, Telix Managing Director and Group CEO said the new structure will optimize the development and commercialization of theranostic radiopharmaceuticals.



NUCLEAR ENERGY

Cameco Corporation (Cameco) – Westinghouse Electric Company LLC. (Westinghouse) announced that China has approved the construction of four Advanced Passive 1000 (AP1000) nuclear reactors for two separate projects. Two reactors will be built at the Bailong nuclear power project in Guangxi province, owned by State Power Investment Corporation Limited, and two at the Lufeng Nuclear Power Plant in Guangdong province, owned by China General Nuclear Power Corporation. This approval increases the total number of operational and approved AP1000 reactors in China to 16. Westinghouse, owned by Cameco and